Research topics
Microbiome articles covering gut bacteria, microbial changes, microbiota research, and IBD disease mechanisms.
Page 11 of 12 · 570 articles
FMT and precision microbiota therapies target the gut ecosystem, a modifiable factor in UC. For people with UC, this review explains potential mechanisms, where FMT has shown benefit in trials, and why it is still...
People with IBD often receive general advice to eat more fiber, but certain purified fibers or fiber-enriched foods may help some people while worsening inflammation in others. Research that teases apart fiber types and...
Tertiary lymphoid organs form in IBD and may influence disease course; understanding how lymphatic S1PR1 controls TLOs could reveal new targets to modify intestinal inflammation without broad immunosuppression.
Understanding gene–microbe interactions that drive site-specific disease in very early-onset Crohn’s could reveal why some children develop ileal versus colonic disease and suggest new approaches to prevention or...
Adherent-invasive E. coli (AIEC) is implicated in Crohn’s disease inflammation in some patients. This review maps possible ways to target AIEC specifically, which could lead to therapies that reduce infection-driven...
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
Identifies a microbiome-derived protein that inhibits a protease linked to epithelial damage in IBD and shows protective effects in lab and mouse models, pointing to a new therapeutic strategy focused on barrier...
The study tests a multi-targeted biohybrid that could—if translated—help address inflammation, oxidative stress, and dysbiosis together, a combination that current single-target IBD treatments often do not address.
Identifies oral microbes that may appear in the gut of people with IBD and PSC, which could help researchers understand disease mechanisms and eventually inform diagnostics or microbiome-targeted strategies.
Animal research shows a postbiotic from Enterococcus faecium altered gut barrier markers and the microbiome in chickens; this may be of scientific interest for gut microbiome and adjuvant research but does not imply...
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
The review suggests MSCs and their exosomes can change the gut microbiome, a factor implicated in IBD and liver disease, pointing to a potential new therapeutic approach. Patients and clinicians interested in future IBD...
The oral microbiome can influence gut microbes and inflammation; understanding this link could lead to new diagnostic markers (saliva) or combined dental–gastroenterology care approaches relevant to people with IBD.
ER stress in intestinal epithelial cells is proposed as a key molecular mechanism in UC development; targeting ER pathways (notably IRE1β) could eventually lead to new treatments that strengthen the gut barrier and...
Dietary strategies that change the gut microbiome are of interest because they might modify inflammation without drugs. This study suggests PEN+ED can shift the microbiome toward a healthier profile in UC, though...
Mitochondrial dysfunction may be a central contributor to UC inflammation and is being targeted by new therapeutic strategies that could lead to different treatment approaches in the future.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...
This study synthesizes randomized trial evidence about the role of gut microbiota in ulcerative colitis and whether fecal microbiota transplantation (FMT) can help induce remission. People with UC may encounter FMT as a...
The study suggests dietary tryptophan might reduce bacterial-induced acute lung injury in the context of colitis by altering gut–lung immune signaling, which could be relevant to IBD patients who are at risk for...
This preclinical study suggests a fermented postbiotic product may protect the colon in a mouse model of ulcerative colitis by altering the microbiome and tryptophan metabolites and by reducing ferroptotic cell death....
This study describes a new nanozyme approach that reduced inflammation and shifted the gut microbiome in mouse colitis models, suggesting a potential future strategy to boost probiotic therapy for IBD by targeting...
Diet is a modifiable factor that appears to change the gut microbiome and may affect symptoms and inflammation in both IBS and IBD; understanding which patterns help could guide practical dietary advice.
The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...
The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...
This review collects preclinical evidence that a traditional Chinese medicine formula (Gegen Qinlian Decoction) may act on inflammation, the gut barrier, immunity, and microbiota — all relevant to ulcerative colitis and...
Macrophages and innate immune signaling are central to how gut inflammation starts and persists in IBD; better understanding these pathways could point to new treatment strategies for people whose disease doesn’t fully...
The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...
The study synthesizes many stool metagenomes to find consistent microbial species, functional pathways, and strain-level differences linked to IBD and to distinctions between Crohn’s disease and ulcerative...
This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...
Researchers are exploring methods to make probiotic therapies more stable through the digestive tract and to deliver anti-inflammatory molecules directly where intestinal inflammation produces high reactive oxygen...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
The study suggests a new host-directed mechanism that helps a common beneficial gut bacterium (Faecalibacterium prausnitzii) colonize and protect the gut lining, and identifies heparan sulfate as a potential way to...
The study suggests that while Crohn's disease produces a shared dysbiotic signature at diagnosis, the specific microbes enriched differ by age — notably oral-associated taxa in children — which could affect research into...
Researchers used machine learning to prioritize microbiome-related regulatory targets in Crohn's disease, which may guide future lab and clinical research into microbial pathways (like butyrate-related metabolism) that...
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
The study targets oxidative stress and the TXNIP/NLRP3 inflammasome axis, both implicated in IBD inflammation and barrier damage. If translatable, nanozyme-assisted probiotic therapy could offer a novel, targeted way to...
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
The gut microbiome differed more in pediatric Crohn’s disease and acute pancreatitis than in IBS or healthy kids, suggesting microbial changes are stronger in organic inflammatory disease and could be targets for future...
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
The study identifies a food-processing method (black tea processing) that increased flavonoids and improved outcomes in a mouse model of colitis, suggesting that specific dietary preparations might influence gut...
New, non-invasive biomarkers and AI-driven multi-omic approaches could make diagnosis and treatment of IBD more precise, helping patients avoid invasive tests and improving chances of choosing effective therapies sooner.
